Jerry Leventhal, MD
Family Medicine · Palm Coast, FLNPI 1558364265
Payments from drug & device makers
Across 561 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Johnson & Johnson$916
- AbbVie$828
- Lilly USA, LLC$775
- plus $3K from 29 others
What the payments were for
- Food & beverage$9,965100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 138 | $1,948 |
| AstraZeneca | 68 | $1,271 |
| Boehringer Ingelheim | 53 | $1,018 |
| Johnson & Johnson | 27 | $916 |
| AbbVie(2 entities) | 49 | $828 |
| Lilly USA, LLC | 50 | $775 |
| Amgen | 26 | $504 |
| Bayer | 16 | $415 |
| GSK | 22 | $341 |
| Amarin Pharma, Inc. | 19 | $251 |
| Novartis | 11 | $216 |
| Merck | 7 | $183 |
| Exact Sciences | 8 | $171 |
| Esperion Therapeutics, Inc. | 6 | $168 |
| Sanofi-aventis U.S. LLC | 11 | $167 |
| Idorsia Pharmaceuticals US Inc | 9 | $145 |
| Pfizer | 6 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Alk-abello, Inc | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $53 |
| Abbott | 2 | $52 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Upsher-smith Laboratories LLC | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Vivus LLC | 2 | $24 |
| Hartmann USA, Inc. | 1 | $24 |
| Medtronic | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Lucid Diagnostics Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,998 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $178,281 |
| JardianceEmpagliflozin | 117 | $152,813 |
| MounjaroTirzepatide | 83 | $95,085 |
| EliquisApixaban | 58 | $83,384 |
| XareltoRivaroxaban | 44 | $46,665 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $44,330 |
| FarxigaDapagliflozin Propanediol | 27 | $23,920 |
| TrulicityDulaglutide | 21 | $23,422 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $22,388 |
| TradjentaLinagliptin | 20 | $20,388 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $20,327 |
| EntrestoSacubitril/Valsartan | 18 | $17,308 |
| VascepaIcosapent Ethyl | 20 | $15,766 |
| MyrbetriqMirabegron | 13 | $14,823 |
| JanuviaSitagliptin Phosphate | 14 | $13,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $1,018 | $195,589154 claims |
| Novo NordiskOzempic | $1,948 | $178,281108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $775 | $118,507104 claims |
| PfizerEliquis | $97 | $83,38458 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,271 | $49,13182 claims |
| Johnson & JohnsonXarelto | $916 | $46,66544 claims |
| GSKTrelegy Ellipta | $341 | $44,33066 claims |
| MerckJanuvia, Janumet | $183 | $19,80226 claims |
| NovartisEntresto | $216 | $17,30818 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $145 | $5,66512 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $13 | $2,19224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Palm Coast
- Sharrell CooperPalm Coast$16.9M
- Chiamaka IhemePalm Coast$10.4M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.